Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.

Kee Thai YeoChee Fu YungPoh Choo KhooSeyed Ehsan SaffariJane Swee Peng SngMee See HowBin Huey Quek

Published in: The Journal of infectious diseases (2022)

In our setting with year-round RSV circulation, palivizumab prophylaxis was effective in reducing RSV hospitalization among high-risk preterm infants of <32 weeks' gestation within the initial 6 months after discharge.

Keyphrases

respiratory syncytial virus
preterm infants
low birth weight
randomized controlled trial
systematic review
gestational age